1-10 of 10
Mario A. Eisenberger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent

Available to Purchase
Mark C. Markowski, Ronald Tutrone, Christopher Pieczonka, K. Gary Barnette, Robert H. Getzenberg, Domingo Rodriguez, Mitchell S. Steiner, Daniel R. Saltzstein, Mario A. Eisenberger, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2789–2795.
https://doi.org/10.1158/1078-0432.CCR-22-0162
Published: 01 July 2022
View article titled, A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Open the PDF for A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent in another window
Includes: Supplementary data
Journal Articles

Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Free
Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi, Giuseppe Galletti, Seaho Kim, Daniel Worroll, John Stewart, Atef Zaher, Ted P. Szatrowski, Karla V. Ballman, Katsuhiro Kita, Shinsuke Tasaki, Yang Bai, Luigi Portella, Brian J. Kirby, Fred Saad, Mario A. Eisenberger, David M. Nanus, Paraskevi Giannakakou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (6): 1880–1888.
https://doi.org/10.1158/1078-0432.CCR-18-0320
Published: 15 March 2019
View article titled, Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Open the PDF for Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY in another window
Includes: Supplementary data
Journal Articles

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

Free
Channing J. Paller, Xian C. Zhou, Elisabeth I. Heath, Mary-Ellen Taplin, Tina Mayer, Mark N. Stein, Glenn J. Bubley, Roberto Pili, Tamaro Hudson, Radhika Kakarla, Muneer M. Abbas, Nicole M. Anders, Donna Dowling, Serina King, Ashley B. Bruns, William D. Wagner, Charles G. Drake, Emmanuel S. Antonarakis, Mario A. Eisenberger, Samuel R. Denmeade, Michelle A. Rudek, Gary L. Rosner, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2): 306–315.
https://doi.org/10.1158/1078-0432.CCR-17-1100
Published: 15 January 2018
View article titled, Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Open the PDF for Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial in another window
Includes: Supplementary data
Journal Articles

MSH2 Loss in Primary Prostate Cancer

Free
Liana B. Guedes, Emmanuel S. Antonarakis, Michael T. Schweizer, Nooshin Mirkheshti, Fawaz Almutairi, Jong Chul Park, Stephanie Glavaris, Jessica Hicks, Mario A. Eisenberger, Angelo M. De Marzo, Jonathan I. Epstein, William B. Isaacs, James R. Eshleman, Colin C. Pritchard, Tamara L. Lotan
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 6863–6874.
https://doi.org/10.1158/1078-0432.CCR-17-0955
Published: 14 November 2017
View article titled, MSH2 Loss in Primary Prostate Cancer
Open the PDF for MSH2 Loss in Primary Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer

Free
Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Franklin Chu, Roberto Pili, Joseph J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist, William J. Edenfield, Khalid Mamlouk, Karen J. Ferrante, Mary-Ellen Taplin
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1356–1363.
https://doi.org/10.1158/1078-0432.CCR-15-1432
Published: 14 March 2016
View article titled, Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Open the PDF for Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer

Free
Dana Rathkopf, Glenn Liu, Michael A. Carducci, Mario A. Eisenberger, Aseem Anand, Michael J. Morris, Susan F. Slovin, Yasutsuna Sasaki, Shunji Takahashi, Seiichiro Ozono, Nga Kit Eliza Fung, Shinta Cheng, Jinping Gan, Marco Gottardis, Mary T. Obermeier, Jyotsna Reddy, Steven Zhang, Blisse J. Vakkalagadda, Leila Alland, George Wilding, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 880–887.
https://doi.org/10.1158/1078-0432.CCR-10-2955
Published: 15 February 2011
View article titled, Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Open the PDF for Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer in another window
Journal Articles

Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy

Free
Eli Rosenbaum, Mohammad Obaidul Hoque, Yoram Cohen, Marianna Zahurak, Mario A. Eisenberger, Jonathan I. Epstein, Alan W. Partin, David Sidransky
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8321–8325.
https://doi.org/10.1158/1078-0432.CCR-05-1183
Published: 01 December 2005
View article titled, Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy
Open the PDF for Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy in another window
Journal Articles

Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial

Free
Eli Rosenbaum, Marianna Zahurak, Victoria Sinibaldi, Michael A. Carducci, Roberto Pili, Menachem Laufer, Theodore L. DeWeese, Mario A. Eisenberger
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (12): 4437–4443.
https://doi.org/10.1158/1078-0432.CCR-04-2252
Published: 15 June 2005
View article titled, Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial
Open the PDF for Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial in another window
Journal Articles

Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy

Free
Patrick J. Bastian, Ganesh S. Palapattu, Xiaohui Lin, Srinivasan Yegnasubramanian, Leslie A. Mangold, Bruce Trock, Mario A. Eisenberger, Alan W. Partin, William G. Nelson
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (11): 4037–4043.
https://doi.org/10.1158/1078-0432.CCR-04-2446
Published: 01 June 2005
View article titled, Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy
Open the PDF for Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy in another window
Journal Articles

A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule

Free
Michael A. Carducci, Jill Gilbert, M. Katherine Bowling, Dennis Noe, Mario A. Eisenberger, Victoria Sinibaldi, Yelena Zabelina, Tian-ling Chen, Louise B. Grochow, Ross C. Donehower
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (10): 3047–3055.
Published: 01 October 2001
View article titled, A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule
Open the PDF for A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule in another window